NIAID BAA: Development of Therapeutic Medical Countermeasures For Biodefense and Emerging Infectious Diseases

 
 
 
 

The National Institute of Alergies and Infectious Diseases (NIAID) has just issued a Braod Agency Announcement (BAA) on Development of Therapeutic Medical Countermeasures For Biodefense and Emerging Infectious Diseases.

Funding: NO CAPON THE BUDGET up to 5 years

Application Due DateOctober 1, 2012

The FreeMind Group has extensive experience in assisting clients in completing and winning such complex and competitive proposals. Through our methodical and proven professional process we will guide your efforts through to submission and subsequent award.

 

Full Solicitation – PDF

Therapeutics supported under this BAA:

Broad spectrum anti-bacterial: Therapeutic with activity against one of the following bacterial pathogens:Bacillus anthracis, Francisella tularensis, Yersinia pestis, Burkholderia pseudomallei, B. mallei, and Rickettsia prowazekii AND in addition, activity against one other NIAID Category A, B and C bacterial threat agent.

Broad spectrum anti-viral: Therapeutic with activity against one of the following viral pathogens: Ebola virus, Marburg virus, Variola major, Dengue virus, Venezuelan encephalitis virus, Western Equine encephalitis virus, and Eastern Equine encephalitis virus AND, in addition, activity against one other NIAID Category A, B and C viral threat agent

Influenza antiviral agents: Therapeutics active against multiple influenza A subtypes directed at either viral or host targets.

Anti-toxins supported under this BAA are specified as the following: A therapeutic agent, particularly a small molecule, with activity against one of the following toxins: Botulinum neurotoxin, Staphylococcus enterotoxin B, Bacillus anthracis Protective Antigen, Lethal Factor or Edema Factor, and ricin toxin.

 

This BAA will NOT support:

  • Basic research and discovery of new candidates/products.
  • Refinement of a lead series to identify a lead candidate.
  • Development of devices or diagnostics.
  • Development of candidates/products that have not demonstrated activity in a relevant animal model of disease.

Full Solicitation – PDF

To schedule a call with a representative from FreeMind please contact Hannah Rosencweig at:

(617) 648-0340hannah@freemindconsultants.com